HPV vaccines: alternative dosage schedules

Area of Science:

• Vaccinology
• Public Health
• Infectious Diseases

Background:

• Human papillomavirus (HPV) VLP vaccines are highly effective against HPV-related diseases when administered on a prime, prime-boost schedule.
• Current two-dose schedules are widely adopted but remain costly and logistically challenging, particularly for low-resource countries.
• Cervical cancer, primarily caused by HPV, disproportionately affects low-resource settings.

Purpose of the Study:

• To evaluate the efficacy of alternative HPV vaccination schedules, including single-dose and extended 1+1 schedules.
• To address vaccine supply constraints and improve the implementation of HPV vaccination programs globally.
• To analyze the long-term effectiveness of reduced-dose HPV vaccination strategies.

Main Methods:

• Review of observational studies and post hoc analysis of randomized control trials (RCTs).
• Investigation of one-dose and extended 1+1 (dose 2 at 3-5 years) schedules in ongoing RCTs.
• Discussion of challenges and opportunities for alternative dosing in the context of vaccine supply limitations.

Main Results:

• One HPV vaccine dose demonstrates effectiveness comparable to two or three doses in preventing persistent infection with vaccine HPV types for at least 7-10 years.
• Immunological response to one dose is inferior to two or three doses, but clinical effectiveness remains high.
• Alternative schedules, including single-dose and 1+1, are under investigation for their long-term efficacy.

Conclusions:

• A single-dose HPV vaccination strategy shows significant promise for long-term protection against persistent HPV infection.
• Alternative dosing schedules could enhance vaccine accessibility and affordability, especially in resource-limited settings.
• Further research and ongoing RCTs are crucial to confirm the long-term effectiveness and optimal implementation of reduced-dose HPV vaccination schedules.